JP2013504537A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504537A5
JP2013504537A5 JP2012528352A JP2012528352A JP2013504537A5 JP 2013504537 A5 JP2013504537 A5 JP 2013504537A5 JP 2012528352 A JP2012528352 A JP 2012528352A JP 2012528352 A JP2012528352 A JP 2012528352A JP 2013504537 A5 JP2013504537 A5 JP 2013504537A5
Authority
JP
Japan
Prior art keywords
hydroxy
dihydro
pyrrolo
oxo
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504537A (ja
Filing date
Publication date
Priority claimed from GBGB0915892.4A external-priority patent/GB0915892D0/en
Application filed filed Critical
Publication of JP2013504537A publication Critical patent/JP2013504537A/ja
Publication of JP2013504537A5 publication Critical patent/JP2013504537A5/ja
Pending legal-status Critical Current

Links

JP2012528352A 2009-09-10 2010-09-08 Ampk活性化因子としてのピロロピリジン誘導体 Pending JP2013504537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0915892.4 2009-09-10
GBGB0915892.4A GB0915892D0 (en) 2009-09-10 2009-09-10 Compounds
PCT/EP2010/063196 WO2011029855A1 (en) 2009-09-10 2010-09-08 Pyrrolo-pyridine derivatives as activators of ampk

Publications (2)

Publication Number Publication Date
JP2013504537A JP2013504537A (ja) 2013-02-07
JP2013504537A5 true JP2013504537A5 (enExample) 2013-10-24

Family

ID=41228136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528352A Pending JP2013504537A (ja) 2009-09-10 2010-09-08 Ampk活性化因子としてのピロロピリジン誘導体

Country Status (5)

Country Link
US (1) US20120172333A1 (enExample)
EP (1) EP2475660A1 (enExample)
JP (1) JP2013504537A (enExample)
GB (1) GB0915892D0 (enExample)
WO (1) WO2011029855A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス,インコーポレイティド ジアゾールアミド
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN107108605A (zh) * 2014-08-27 2017-08-29 盐野义制药株式会社 具有ampk活化作用的氮杂吲哚衍生物
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
EP4066832A4 (en) * 2019-11-14 2024-01-03 Zincure Corp. Pharmaceutical composition for treating multiple sclerosis on basis of ampk inhibitory function and zinc homeostasis control function
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
US11857346B2 (en) 2021-05-25 2024-01-02 Warsaw Orthopedic, Inc. Systems and methods for real-time monitoring of bone correction
AU2022391025A1 (en) 2021-11-19 2024-06-06 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
UA106037C2 (uk) * 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)

Similar Documents

Publication Publication Date Title
AU2010231630B2 (en) Medical composition for treatment or prophylaxis of glaucoma
JP6853619B2 (ja) シアノトリアゾール化合物の医薬用途
JP6503336B2 (ja) シアノトリアゾール化合物
JP4408627B2 (ja) 置換アルキルアミン誘導体およびそれの使用方法
JP2016164184A5 (enExample)
CA2647338A1 (en) Integrase inhibitors-3
JP6251277B2 (ja) ROR−ガンマ−tのフェニル結合キノリニルモジュレーター
RU2011147206A (ru) Азетидинилдиамиды в качестве ингибиторов моноацилглицеринлипазы
JP6067181B2 (ja) アルドステロンシンターゼ阻害薬
AU2007256708A1 (en) Organic compounds
JP2009510161A5 (enExample)
JP2020526556A5 (enExample)
TW200529830A (en) A thiazole derivative
AU2003252011A1 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
JP2014520885A5 (enExample)
AU2009224329A1 (en) Pyridylaminoacetic acid compound
JP2014532626A5 (enExample)
JP2007516173A5 (enExample)
KR20080051157A (ko) 트리아릴카르복시산 유도체
JP2020526547A5 (enExample)
RU2016111659A (ru) Соединение с агонистической активностью в отношении рецепторов соматостатина и его фармацевтическое применение
JP2012514577A5 (enExample)
JPWO2006016548A1 (ja) ヘテロ環化合物を含有する新規な抗マラリア剤
JP2018502881A5 (enExample)
HRP20210052T1 (hr) Modulatori adenozinskog receptora a3